Home › Sub-Optimal 39% Hep C Cure Rate Keeps Merck In Gilead's Rear View
 

Keywords :   


Sub-Optimal 39% Hep C Cure Rate Keeps Merck In Gilead's Rear View

2014-11-13 14:42:27| Biotech - Topix.net

Until Merck's product can deliver an optimal cure rate at a cheaper price, it poses no threat to Gilead's Harvoni. Merck's attempt to compete with Gilead in finding a cure for hepatitis C has fallen short .

Tags: view rate rear cure

Category:Biotechnology and Pharmaceuticals

Latest from this category

All news
»
06.11Hurricane Rafael Update Statement
06.11Summary for Hurricane Rafael (AT3/AL182024)
06.11Warning millions will struggle to pay water bill rises
06.11Atlantic Tropical Weather Outlook
06.11Tropical Storm Rafael Graphics
06.11Tropical Storm Rafael Public Advisory Number 9A
06.11Summary for Tropical Storm Rafael (AT3/AL182024)
06.11Eastern North Pacific Tropical Weather Outlook
More »